This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 (CT04)

This study has been completed.
Information provided by (Responsible Party):
CERESPIR Identifier:
First received: February 23, 2011
Last updated: December 2, 2015
Last verified: December 2015
To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.

Condition Intervention Phase
Alzheimer's Disease Drug: CHF 5074 1x Drug: CHF 5074 2x Drug: CHF 5074 3x Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment

Resource links provided by NLM:

Further study details as provided by CERESPIR:

Primary Outcome Measures:
  • Differences in ∆sCD40L Levels Between CHF 5074 Doses and Placebo at Any Specific Time Point [ Time Frame: up to 12 weeks ]
    To assess if there were differences in ΔsCD40L levels between CHF 5074 doses and placebo

Secondary Outcome Measures:
  • Measurement of Trough CHF 5074 Plasma Levels [ Time Frame: Days 85 ]
    evaluate the pharmacokinetics (PK) of CHF 5074 in patients with MCI.

  • Changes in Plasma ΔTNFα Concentrations [ Time Frame: 29 days ]

Enrollment: 96
Study Start Date: March 2011
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CHF 5074 1x
oral tablet, multidose
Drug: CHF 5074 1x
oral tablet, 1x, once a day in the morning for 12 weeks
Experimental: CHF 5074 2x
oral tablet, multidose
Drug: CHF 5074 2x
oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
Experimental: CHF 5074 3x
oral tablet, multidose
Drug: CHF 5074 3x
oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
Placebo Comparator: Placebo
placebo, oral tablet, multidose
Drug: Placebo
oral tablet, once a day in the morning for 12 weeks


Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of amnestic or non-amnestic Mild Cognitive Impairment.
  • Mini-Mental State Examination score higher than 24 at screening.
  • MRI scan of the brain at screening with fluid-attenuation inversion recovery (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences.

Exclusion Criteria:

  • Diagnosis of Alzheimer's disease according to the (DSM-IV-TR) or NINCDS-ADRDA criteria.
  • Any medical condition that could explain the patients cognitive deficits.
  • CT or MRI brain imaging results obtained within 12 months prior to baseline showing evidence of infection, infarction, or focal lesions of clinical significance
  • MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with diameter ≤ 10 mm).
  • Geriatric Depression Scale (30-point scale) score > 9 at screening.
  • History of stroke.
  • Modified Hachinski ischemic scale score > 4 at screening.
  • Women of childbearing potential.
  • Vitamin B12 or folate deficiency.
  • Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar disorders) within 3 years of screening.
  • Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year and/or chronic inflammatory bowel disease.
  • Concomitant use of donepezil at doses > 5 mg/day or other cholinesterase inhibitors (rivastigmine or galantamine) at any dose.
  • Concomitant use of memantine at dose > 20 mg/day.
  • Concomitant use of psychoactive drugs (sedatives, hypnotics, etc).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01303744

United States, Florida
Comprehensive NeuroScience, Inc.
St. Petersburg, Florida, United States, 33716
United States, New Jersey
Memory Enhancement Center of America, Inc.
Eatontown, New Jersey, United States, 07724
Memory Center of New Jersey, Inc.
Monroe Twp, New Jersey, United States, 08831
Memory Enhancement Center of NJ, Inc.
Toms River, New Jersey, United States, 08755
United States, Texas
Senior Adults Specialty Research
Austin, Texas, United States, 78757
Clinica Santa Maria, Div Neurologia
Castellanza, Italy
Osp. Maggiore Policlinico, Clin. Neurol
Milano, Italy
Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze
Milano, Italy
Nuovo Osp Civ S. Agostino Estense, Dip di Neuroscienze
Modena, Italy
Sponsors and Collaborators
Principal Investigator: Joel S. Ross, MD Memory Enhancement Center of America, Inc.
Principal Investigator: Gabriella Bottini, Prof. Osp. Niguarda Ca Granda
  More Information

Responsible Party: CERESPIR Identifier: NCT01303744     History of Changes
Other Study ID Numbers: CCD-1014-PR-0053
2010-024270-19 ( EudraCT Number )
Study First Received: February 23, 2011
Results First Received: October 16, 2015
Last Updated: December 2, 2015

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on September 21, 2017